- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesStock PickerFinancial DiaryUK IndicesUK Industry SectorsCompany LookupShare RisersShare FallersBroker RatingsFinance GlossarySMS ServicesShare ChatFinance NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
Epistem ShareCast News (EHP)
ShareCast News for Epistem (EHP)
| Share Price: 555.00 | Bid: 555.00 | Ask: 570.00 | Change: -7.50 (-1.33%) |  | ||||||
| ||||||||||
Maiden pre-tax profit for Epistem
Tue, 5th Oct 2010 13:28
UK biotech company, Epistem, celebrates the full year results with a maiden pre-tax profit since becoming an AIM-listed company in 2007.
The group has swung to a pre-tax profit of £0.35m, from last year's loss of £0.67m. Revenues rose 45% to £5.7m, from £4.0m previously, as sales rose across all divisions.
Epistem has also unveiled a new diagnostic mobile service, called Genedrive?, for 'on the spot' patient diagnosis. The new device has been incorporated into the Personalised Medicine division.
Following these results, the broker KBC Peel Hunt, has kept a buy rating and 515p target price, suggesting a 50% upside to the current price.
CEO, Matthew Walls said, "the Personalised Medicine market is forecast to grow considerably over the next few years."
The group has swung to a pre-tax profit of £0.35m, from last year's loss of £0.67m. Revenues rose 45% to £5.7m, from £4.0m previously, as sales rose across all divisions.
Epistem has also unveiled a new diagnostic mobile service, called Genedrive?, for 'on the spot' patient diagnosis. The new device has been incorporated into the Personalised Medicine division.
Following these results, the broker KBC Peel Hunt, has kept a buy rating and 515p target price, suggesting a 50% upside to the current price.
CEO, Matthew Walls said, "the Personalised Medicine market is forecast to grow considerably over the next few years."
1
Epistem to raise 4.3m pounds via placing
Epistem, a biotechnology and personalised medicine company is to raise 4.3m pounds before expenses through a placing of approximately 793.4m shares at 545p a share.[7 Dec '12]
Investec invests in Epistem
Investec Asset Management has taken a 7.05 per cent stake in Epistem, a biotech firm working in the area of personalised medicine.[24 Oct '12]
Epistem delivers steady performance
Biotechnology firm Epistem has delivered steady full-year results, while also accelerating investment in a number of its core development programmes.[16 Oct '12]
Epistem secures contract for TB test
EpiStem, the pre-clinical drugs test firm, has reported that full year trading has been broadly in-line with market forecasts.[6 Aug '12]
Small caps round-up: Epistem, Stadium Group, Trading Emissions
Biotechnology firm Epistem Hldings said it had received the go-ahead to sells its new tuberculosis product in EEA member state markets. The firm said its Genedrive units provided a major advance in next generation molecular diagnostic testing. Epistem is now preparing regulatory submissions for India, which has the largest number of TB sufferers in the world.[5 Jul '12]
Big things expected of EpiStem's Genedrive device
Epistem, the biotechnology company specialising in diagnostic aids for the treatment of cancer and gastrointestinal diseases, continued on its steady growth path last year.[11 Oct '11]
Epistem sees solid growth
Adult stem cell specialist Epistem scraped into profit in the first half of its financial year.[29 Mar '11]
Maiden pre-tax profit for Epistem
UK biotech company, Epistem, celebrates the full year results with a maiden pre-tax profit since becoming an AIM-listed company in 2007.[5 Oct '10]
1
